ALDX Financials: Aldeyra Therapeutics Inc AI Analysis

Home

Stock

ALDX

Financials

ALDX Financial

Aldeyra Therapeutics Inc

$1.85

-1.06%

$-0.02

At close: Mar 25, 16:00:00 GMT-4

$1.85

Post-market: Mar 25, 16:58:13 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$1.87

Open

$1.98

Day's Range

$1.76 - $2.02

52 week range

$1.07 - $6.8

Volume

4.5M

Avg.Volume

2.4M

Dividend yield

EPS (TTM)

-0.56

Market Cap

$111.3M

What is ALDX?

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. The company is headquartered in Lexington, Massachusetts. The company went IPO on 2014-05-02. The firm's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.



Features

AI Copilot for Stock & Crypto

Resources

Market

Income

Balance sheet

Cash flow

Annual

Quarterly

ALDX Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021
Revenue	0	0	0	0	0	0
Revenue Growth (YoY)	--	--	--	--	--	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	9	9	11	13	15	11
Research & Development	25	25	48	29	47	44
Operating Expenses	35	35	60	42	62	56
Other Non Operating Income (Expenses)	--	--	--	--	--	--
Pretax Income	-33	-33	-55	-37	-62	-57
Income Tax Expense	--	--	--	--	--	0
Net Income	-33	-33	-55	-37	-62	-57
Net Income Growth	-40%	-40%	49%	-40%	9%	54%
Shares Outstanding (Diluted)	60.16	60.05	59.48	58.94	58.41	54.04
Shares Change (YoY)	1%	1%	1%	1%	8%	59%
EPS (Diluted)	-0.56	-0.56	-0.93	-0.63	-1.06	-1.07
EPS Growth	-40%	-40%	47%	-40%	-1%	-4%
Free Cash Flow	-33	-33	-43	-30	-56	-42
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	--	--	--	--	--	--
Operating Margin	0%	0%	0%	0%	0%	0%
Profit Margin	0%	0%	0%	0%	0%	0%
Free Cash Flow Margin	0%	0%	0%	0%	0%	0%
EBITDA	-35	-35	-60	-42	-62	-56
EBITDA Margin	0%	0%	0%	0%	0%	0%
D&A For EBITDA	0	0	0	0	0	0
EBIT	-35	-35	-60	-42	-62	-56
EBIT Margin	0%	0%	0%	0%	0%	0%
Effective Tax Rate	--	--	--	--	--	0%

Follow-Up Questions

What are Aldeyra Therapeutics Inc's key financial statements?



According to the latest financial statement (Form-10K), Aldeyra Therapeutics Inc has a total asset of $72, Net loss of $-33

What are the key financial ratios for ALDX?



Aldeyra Therapeutics Inc's Current ratio is 2.66, has a Net margin is 0, sales per share of $0.

How is Aldeyra Therapeutics Inc's revenue broken down by segment or geography?



Aldeyra Therapeutics Inc largest revenue segment is Digital & Integration, at a revenue of 3,871,000,000 in the most earnings release.For geography, North America is the primary market for Aldeyra Therapeutics Inc, at a revenue of 7,515,000,000.

Is Aldeyra Therapeutics Inc profitable?



no, according to the latest financial statements, Aldeyra Therapeutics Inc has a net loss of $-33

Does Aldeyra Therapeutics Inc have any liabilities?



yes, Aldeyra Therapeutics Inc has liability of 27

How many outstanding shares for Aldeyra Therapeutics Inc?



Aldeyra Therapeutics Inc has a total outstanding shares of 60.16

Aldeyra Therapeutics Inc (ALDX) Financial

ALDX Stock Price Chart